Pharma News

The Institute of Pharmacy has been established with a view to promote excellence in pharmaceutical education and to prepare young men and women to meet the challenges in the area of pharmaceutical industries, education, research and development and marketing. We aim to provide degree, postgraduate, doctoral and postdoctoral level education at this centre of excellence. The pharmacy profession in Gujarat and western part of India has been striving for such a centre and establishment of IP.

The US health regulator has imposed an import ban on products made at Dr Reddy's Laboratories' Mexican plant for violation of current good manufacturing practices (CGMP).

The FDA has sent a warning letter to Cadila Healthcare’s Ahmedabad, India finished products plant after an inspection found GMP deviations.

Glenmark Pharmaceuticals today announced the settlement of litigation with Daiichi Sankyo and Genzyme Corporation regarding Glenmark's Abbreviated New Drug Application (ANDA) tiled with the US Food and Drug Administration (FDA) for Colesevelam Hydrochloride, a drug used in treatment of type-2 diabetes.

Cognitive Science is the study of the processes by which the humans and other animals come to know properties of their external environment and convert that knowledge into action as well as relay that knowledge to others by means of communication. As a result, Cognitive Science has a vital role to play in several socially important areas such as mental health, social engineering, education and computer technology.

BIT, Mesra is a "Deemed University" under Sec. 3 of the U.G.C. Act 1956.

India has, so far, failed to get any assurance from the European Union to reconsider its ban on Indian herbal medicines even though the issue was raised at the EU through the official channel several times.

The ban has come into effect from May 1, 2011, following a new EU regulatory procedure that was approved seven years back.

ABOUT GANPAT UNIVERSITY

The New England Journal of Medicine (NEJM) published a study that shows Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival (PFS), or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET)[1].